Physician profile
Jonathan M Guy
NPI 1447799457
$820.34
in general payments reported to CMS, 2019-2025
23 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.66 · 2022: $15.19 · 2023: $501 · 2024: $17.04 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $274.16 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $71.87 | 2023 | Ultomiris, Soliris |
| Abbvie INC. | $38.44 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $32.35 | 2023 | Xeomin |
| Sk Life Science, INC. | $30.20 | 2023 | |
| Baxter Healthcare | $28.38 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Tanabe Pharma America, INC. | $24.58 | 2023 | |
| Boston Scientific Corporation | $24.10 | 2023 | Watchman Flx |
| Amylyx Pharmaceuticals, INC. | $23.41 | 2023 | Relyvrio |
| Scilex Pharmaceuticals INC. | $22.91 | 2023 | Ztlido |
| Lilly USA, LLC | $22.85 | 2023 | Amyvid |
| Alnylam Pharmaceuticals INC. | $22.76 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $21.86 | 2023 | Invega Sustenna |
| Impel Pharmaceuticals INC. | $21.22 | 2023 | Trudhesa |
| Neurelis, INC. | $20.70 | 2023 | Valtoco |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.55 | 2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $20.03 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $19.30 | 2023 | |
| Octapharma USA, INC. | $19.23 | 2023 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $18.53 | 2023 | Austedo Xr |
| Indivior INC. | $15.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.06 | 2023 | |
| Dexcom, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.